This page is translated by Google and can contain errors. Go back to English.

Obtain a grant to develop your pancreatic cancer research idea

The Anticancer Fund invests in more and better treatments for pancreatic cancer patients

BRUSSELS – The Anticancer Fund launches a new grant initiative targeting academic researchers in the field of pancreatic cancer. This grant aims to facilitate the transition of promising research into clinical trials, by providing the necessary resources and expertise.

 

The primary objective of this grant is to support academic researchers in advancing their preclinical discoveries into clinical trial proposals. The successful translation of good preclinical research into a clinical project partly relies on the ability of researchers to obtain the necessary expertise and securing adequate time and funding.

By offering seed funding dedicated to the development of research protocols, the Anticancer Fund fosters high-quality clinical trials in pancreatic ductal adenocarcinoma. We are interested in interventions with robust preclinical data on pancreatic ductal adenocarcinoma that are ready for clinical trials.

PDAC is an aggressive type of cancer

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, accounting for about 90% of cases. Less than 10% of the patients with this particularly aggressive type of cancer live longer than 5 years after their diagnosis, and the average survival time is only about 4-6 months if no treatment is given. These numbers emphasize the pressing need for new and effective therapeutic approaches, and why this research grant is so important.

We plan to fund two proposals

Each project selected will receive a grant of 25,000 €, earmarked for the costs of staff needed to draft and develop the clinical trial protocol. We anticipate awarding two projects.

The application is straightforward and requires only one submission step.

Find the guidelines and application form here.


The deadline for submissions is set for Tuesday 1 October 2024, 23:59 CET.


The final selection is expected to be communicated in December 2024 with a starting date in the first half of 2025.

The Anticancer Fund urges scientists working on pancreatic cancer to apply for this grant. Your research could lead to breakthroughs that extend lives and improve the quality of life for patients around the world.

 

More on how we fight pancreatic cancer

During Pancreatic Cancer Awaress Month, the Anticancer Fund redoubles its efforts

Our clinical trials in pancreatic cancer

Joint efforts with Pancreatic Cancer Europe